tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

hVIVO to Present at Europe’s Largest Healthcare Conference

Story Highlights
  • hVIVO plc is a leader in human challenge trials, offering comprehensive clinical services.
  • hVIVO’s CEO will present at the Jefferies Global Healthcare Conference, highlighting its industry role.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
hVIVO to Present at Europe’s Largest Healthcare Conference

Meet Your ETF AI Analyst

Open Orphan Plc ( (GB:HVO) ) has provided an update.

hVIVO plc announced that its CEO, Yamin ‘Mo’ Khan, will present at the Jefferies Global Healthcare Conference in London on November 20, 2025. This event, the largest healthcare-dedicated conference in Europe, will host over 700 companies and 3,600 attendees. While no new material information will be disclosed, the presentation underscores hVIVO’s prominent role in the healthcare sector and its commitment to engaging with key industry stakeholders.

The most recent analyst rating on (GB:HVO) stock is a Hold with a £7.50 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.

Spark’s Take on GB:HVO Stock

According to Spark, TipRanks’ AI Analyst, GB:HVO is a Neutral.

Open Orphan Plc’s stock score is primarily driven by its strong financial performance and attractive valuation. However, technical indicators suggest bearish momentum, which could pose a risk to short-term price movements. The lack of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on GB:HVO stock, click here.

More about Open Orphan Plc

hVIVO plc is a full-service early phase Contract Research Organisation (CRO) and a global leader in human challenge trials. The company provides comprehensive clinical development services, specializing in human challenge trials for infectious and respiratory diseases. It operates the largest quarantine facility in London and offers virology and immunology laboratory services under the hLAB brand. Through its subsidiaries, CRS and Venn Life Sciences, hVIVO offers early-phase clinical trial services and drug development consulting, supporting a seamless pathway from preclinical stages to late-stage development.

Average Trading Volume: 2,164,181

Technical Sentiment Signal: Sell

Current Market Cap: £45.21M

Find detailed analytics on HVO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1